CELULARITY INC-A

CELU stock represents shares of Celularity Inc., a clinical-stage biotechnology company. The company focuses on developing cellular therapies derived from postpartum human placenta for oncology, immunology, and regenerative medicine applications. CELU trades on the Nasdaq Capital Market under the ticker symbol CELU. As a clinical-stage company, its value is closely tied to the progress of its therapeutic pipeline and related regulatory milestones.

CELU stock can be influenced by clinical trial results, regulatory decisions from the FDA, and changes in the competitive landscape for cellular therapies. Financing activities, cash runway updates, and partnership announcements often matter for clinical-stage biotech companies. Broader market sentiment toward biotechnology, interest rate expectations, and small-cap volatility can also move the shares. Because CELU is a smaller-cap company, news flow can have an outsized effect on its price.

Valuing a clinical-stage biotech like CELU often relies less on traditional earnings multiples, since it may not have consistent profits. Investors commonly review cash position, burn rate, pipeline progress, and potential market opportunities for its therapies. Price-to-book, enterprise value, and cash per share can provide context, but they are only part of the picture. For the latest valuation metrics and market data, refer to the CELU quote and financial summary on this page.

CELU shares can be purchased through a brokerage account that offers access to U.S. stock exchanges. Investors typically search for the ticker CELU, place a market or limit order, and specify the number of shares they want to buy. Some brokers also support fractional shares, allowing investment with a smaller dollar amount. Trading availability, fees, and order types depend on the individual brokerage platform.

CELU may be eligible for pre-market and after-hours trading through certain brokers, but extended-hours sessions often have lower liquidity and wider spreads. Trades outside regular U.S. market hours may also be limited to specific order types and may not be available on all platforms. Because prices can move quickly on news released outside regular hours, investors should check with their brokerage about extended-hours trading rules and risks. Intraday data shown on this page may reflect the latest regular or extended session.

As a clinical-stage biotechnology company, CELU faces risks such as disappointing clinical trial outcomes, regulatory delays, and the need for additional capital to fund research and operations. Its financial performance may be uneven, and the shares can be volatile, especially for a smaller-cap stock. Competitive pressures, intellectual property challenges, and changes in healthcare policy could also affect the business. Reviewing SEC filings and the latest company updates can help investors understand these risks more fully.